Rhythm生物科学公司启动了一项新的基于基因的测试,以便更好地预测直肠癌风险,并促进早期发现。 Rhythm Biosciences launched a new gene-based test to better predict colorectal cancer risk and boost early detection.

节奏生物科学公司推出了更新的geneTypeTM结肠直肠癌风险评估测试,该测试使用140-SNP多基因风险得分与临床和生活方式因素相结合,以更好地预测性别和年龄组的结肠直肠癌风险. Rhythm Biosciences has launched an updated geneType™ Colorectal Cancer Risk Assessment test that uses a 140-SNP polygenic risk score combined with clinical and lifestyle factors to better predict CRC risk across genders and age groups. 经SPLOS one(2025年)验证,强化测试提高了早期检测的准确性,支持有针对性地使用其ColoSTAT血液检测,并可能有助于通过改变生活方式预防多达一半的病例。 Validated in PLOS ONE (2025), the enhanced test improves early detection accuracy, supports targeted use of its ColoSTAT blood test, and may help prevent up to half of cases through lifestyle changes. 该工具旨在提高筛查参与率,特别是年轻成人和妇女的筛查参与率,并在澳大利亚等筛查合规率低的地区改进个性化监测。 The tool aims to boost screening participation, especially among younger adults and women, and improve personalized monitoring in regions like Australia with low screening compliance.